深圳"20+8"新兴产业集群政策将迎"3.0版"。 去新兴产业增加值1.67万亿 "20+8"产业集群政策实施至今，深圳经济规模稳步扩大、产业结构持续优化。据政府工作报告，"十四 五"期间，深圳GDP年均增长5.5%，增速居一线城市首位。 新质生产力发展走在前列，战略性新兴产业增加值从2020年的1.03万亿元提高到1.67万亿元，占GDP比 重达43%，先进制造业增加值占规上工业比重达68.4%。 其中，智能终端集群规模迈上万亿元台阶，网络与通信、软件与信息服务、智能网联汽车3个集群规模 均突破8000亿元，数字经济核心产业增加值连续3年破万亿元，集成电路、工业机器人、智能手机等39 种工业产品产量占全国比重超10%。 2月9日，深圳市七届人大七次会议开幕。深圳市市长覃伟中作政府工作报告时透露，2026年，深圳将制 定实施"20+8"战略性新兴产业集群和未来产业政策体系3.0版，战略性新兴产业增加值目标增长7%以 上。 数据显示，2025年，深圳全市战略性新兴产业增加值1.67万亿元，占地区生产总值比重提高至43.0%。 2026年是"十五五"的开局之年，按照规划，深圳战略性新兴产业增加值的增长目标在7%以 ...

Core Viewpoint - The A-share photovoltaic sector experienced a surge in stock prices, with multiple companies reaching their daily limit, driven by a significant patent licensing agreement between Aiko Solar and TCL Zhonghuan's subsidiary Maxeon, involving a total licensing fee of 1.65 billion yuan [1][3]. Group 1: Patent Licensing Agreement - Aiko Solar and TCL Zhonghuan signed a patent licensing agreement allowing Aiko to access all BC battery and component patents owned by Maxeon, excluding reverse licensing [1][3]. - The total licensing fee is 1.65 billion yuan, with the first-year payment set at 250 million yuan, marking the largest publicly disclosed patent licensing fee in China's photovoltaic industry to date [1][3]. - The agreement resolves ongoing patent disputes between Aiko and Maxeon, including previous lawsuits in Germany and the Netherlands regarding BC technology [3]. Group 2: Market Impact and Company Performance - Following the announcement, Aiko Solar's stock price reached 14.92 yuan per share, with a market capitalization of 31.6 billion yuan, while TCL Zhonghuan's stock was at 11.68 yuan per share, with a market cap of 47.2 billion yuan [4]. - Aiko Solar anticipates that the licensing fees will be covered by projected sales exceeding 165 GW over the next five years, with an average cost of less than 0.01 yuan per watt for licensing [4]. - The licensing model based on BC technology is expected to become a new profit growth point for Aiko Solar [4]. Group 3: Industry Context - Patent disputes are common in the photovoltaic industry, with many leading manufacturers involved in ongoing legal battles over technology rights [3][4]. - The emphasis on intellectual property protection is increasingly recognized within the photovoltaic sector, as highlighted by recent discussions on industry governance and the need for coordinated efforts to balance supply and demand [8].

港股保险板块的表现同样惊艳，与A股形成呼应。截至午间收盘，众淼控股大涨41.78%，中国人寿H股 涨幅达4.51%，中国平安H股上涨4.09%，云锋金融、阳光保险等头部险企涨幅显著。 此番板块异动背后，是存款利率下行与行业基本面的持续改善。在此背景下，以分红险为代表的储蓄险 凭借收益更高、期限更长、兼具保障功能的优势，成为居民资产配置的重要选择，为保险行业增长注入 强劲动力。 根据国家金融监督管理总局披露的数据，2025年，我国保险业原保险保费收入首次突破6万亿元大关， 达到6.12万亿元，同比增长7.4%；行业总资产达41.31万亿元，较年初增长15.1%。 而上市险企的盈利表现更是亮眼。2025年前三季度，A股五大上市险企合计实现归母净利润4260亿元， 同比增长33.5%，刷新历史纪录。其中，中国人寿实现归母净利润1678.04亿元，同比增长60.5%；新华 保险实现归母净利润328.57亿元，同比增长58.9%。其余三家险企也实现两位数增长。中国平安、中国 人保、中国太保分别实现归母净利润1328.56亿元、468.22亿元、457亿元，分别同比增长11.5%、 28.9%、19.3%。 2月9日早盘 ...

南方财经2月9日电，港股风电股午后拉升，东方电气涨超13%，金风科技、瑞风新能源跟涨。 ...

菲利华：2025H1公司石英电子布实现销售收入1312.48万元，产品目前处于客户小批量测试及终端客户 认证阶段。 莱特光电：目前已经组建具备Q布研发生产经验的团队，并且已购置部分生产设备。 宏和科技：公司生产的高性能电子布产品目前已进入行业内多家龙头覆铜板厂商的供应链并实现销售。 现有高性能电子布产品的主要客户台光电子、斗山电子、台燿科技、生益科技、松下集团等均为全球前 十大覆铜板厂商。 南方财经2月9日电，玻璃玻纤板块持续活跃，金晶科技涨停，宏和科技涨超6%，国际付出、三峡新 材、中材科技等跟涨。 消息面上，据智通财经，AI芯片需求的爆发导致T型玻璃纤维布供应趋紧。其主要供应商日东纺计划自 今年年底起稳步提升产能，目标在2028年前将产能提升至2025年的三倍。日东纺表示，即便新生产线投 产，仍难以弥合供给与快速增长需求之间的差距，计划于今年上调价格。花旗分析师预计，涨价幅度可 能达到25%甚至更高。此轮涨价很可能传导至下游，推高智能手机和笔记本电脑的终端售价。 根据公开资料梳理的一些相关个股： 中材科技：全资子公司泰山玻纤陆续成功研发并量产高速覆铜板用低介电纤维布、超低损耗低介电纤维 布及封装用低膨胀纤 ...

消息面上，据珠免集团消息，2月8日，珠海免税拱北口岸进境免税店苹果Apple专区正式启幕。这不仅 标志着苹果首次进驻中国口岸进境免税渠道，也标志着智能电子产品首次正式进入口岸进境免税销售场 景。这是财政部等五部门发布《关于完善免税店政策支持提振消费的通知》后，全国首个实现智能电子 产品落地开业的口岸进境免税项目。 兴业证券：当前免税板块基本面筑底回升确认，未来仍存政策利好催化，建议持续予以关注中国中免、 珠免集团。 南方财经2月9日电，免税概念持续活跃，珠免集团涨停，中国中免涨超5%，海南发展、海峡股份等跟 涨。 ...

Group 1: Technology Industry Developments - Tencent's WeChat has allowed the copying of the red envelope codes for Alibaba's Qianwen app and Tencent's Yuanbao, after previously banning them [2] - OpenClaw has gained significant attention, with investor and entrepreneur Wang Huiwen inviting teams interested in this area to seek funding [3] - Alphabet's Gemini application has surpassed 750 million monthly active users, with a capital expenditure target for 2026 raised to $185 billion, focusing on AI data centers and infrastructure [4] Group 2: Corporate Announcements and Financials - Meitu announced a projected net profit growth of 60% to 66% for the fiscal year 2025 compared to 2024 [8] - ZhuiMi's CEO revealed that the total year-end bonus pool will reach approximately $1 billion, with the highest individual bonuses potentially reaching 20 months' salary [7] Group 3: Product Launches and Innovations - OpenAI's first hardware, named Dime, is expected to be released this year, focusing on a simpler AI audio headset rather than a complex device [9] - Qingtian Rental launched a 999 yuan experience plan for various robots, making advanced robotics accessible to consumers [10] Group 4: Space Exploration and Recruitment - Elon Musk emphasized the need for a large-scale return to the Moon, with SpaceX actively recruiting engineers for AI satellite and space data center development [5] - Musk also revealed that Apple had aggressively recruited Tesla engineers for its now-canceled electric vehicle project, with over 300 employees poached by 2019 [6]

Core Viewpoint - Shanghai Aiyu New Energy Co., Ltd. has signed a patent licensing agreement with Maxeon Solar Pte. Ltd., acquiring all BC battery and component patents outside the U.S. for the next five years, with a total licensing fee of RMB 1.65 billion [3][4]. Group 1: Patent Licensing Agreement - The agreement allows Aiyu to obtain past and future patents from Maxeon, excluding reverse licensing [3][4]. - The total licensing fee is RMB 1.65 billion, to be paid in installments over five years, with the first-year fee set at RMB 250 million [3][4]. - Both parties have agreed to withdraw or terminate all ongoing or pending legal proceedings related to the licensed patents and products [3][4]. Group 2: Market Impact - Following the announcement, the A-share photovoltaic sector experienced a surge, with multiple companies, including Aiyu and TCL Zhonghuan, hitting the daily limit [4]. - The licensing agreement is seen as a resolution to previous patent disputes between Aiyu and Maxeon, which had involved litigation in Europe [5][6]. Group 3: Industry Context - Patent disputes are common in the photovoltaic industry, with many leading companies involved in such conflicts [7]. - Aiyu anticipates that the licensing fees will be covered by projected sales exceeding 165 GW over the next five years, with an average cost of less than 1 cent per watt for the licensing [7]. - The focus on intellectual property rights is becoming a consensus in the photovoltaic industry, with calls for enhanced protection and risk management [8].

Core Insights - Didi is launching various promotional activities and subsidies to support travel during the Spring Festival and Spring Transportation period, including discounts on rides and driver incentives [1][2][3] Group 1: Travel Demand and Promotions - Didi predicts a 45% increase in intercity ride-hailing demand before the Spring Festival compared to the pre-Spring Transportation period [1] - Demand for rides to major transportation hubs like airports and train stations is expected to rise by 40% [1] - Specific increases in demand include a 67% rise for beauty and hair services and a 49% rise for shopping [1] - Didi is offering discounts of up to 60% in over 100 cities starting February 6, with limited-time coupons available for users [2] Group 2: Driver Support and Incentives - Didi plans to distribute 1.1 billion yuan in driver subsidies during the Spring Festival, encouraging drivers to provide quality service [3] - From February 10 to 24, drivers can access various subsidies, including a low-cost commission-free card and a maximum 25% increase in earnings through a revenue acceleration card [3] - Additional incentives include daily rewards for completing specific orders, with potential earnings of up to 140 yuan per day [3] Group 3: Driver Appreciation Initiatives - Didi is hosting "Spring Festival Family Banquets" for drivers in cities like Fuzhou and Shanghai, distributing over 140,000 gift boxes to show appreciation [4] Group 4: Enhanced Travel Experience - Didi has introduced features like "Fare Guardian" and "Trip Guardian" to ensure a smooth travel experience, including fare compensation and priority ride requests [6] - The company is enhancing its real-time guidance features at airports and train stations to facilitate easier pick-up for users [6] - Didi is forming a Spring Transportation support fleet to increase capacity during peak travel times [6]

Core Viewpoint - The strategic collaboration between Innovent Biologics and Eli Lilly aims to advance global research and development of innovative drugs in oncology and immunology, with Innovent leading the development in China and retaining rights in the Greater China region while granting Eli Lilly exclusive rights outside this area [1][3]. Group 1: Collaboration Details - Innovent Biologics will receive an upfront payment of $350 million and is eligible for up to $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1]. - The collaboration structure is designed to accelerate Innovent's global development pipeline, marking a new model for cooperation in the industry [1]. - This partnership is the seventh collaboration between Innovent and Eli Lilly, highlighting a long-standing relationship that has included significant financial and developmental support [5]. Group 2: Financial Impact - Following the announcement of the collaboration, Innovent's stock surged nearly 7%, reaching HKD 85 per share, with a market capitalization of HKD 147.6 billion [1]. - Innovent's revenue for 2025 is projected to reach approximately CNY 11.9 billion, a 45% increase year-on-year, marking the first time product revenue exceeds CNY 10 billion [10]. - The company aims to achieve CNY 20 billion in product revenue by 2027 and plans to advance five core pipelines into global Phase III clinical trials by 2030 [10]. Group 3: Market Position and Future Outlook - The collaboration reflects a broader trend where multinational pharmaceutical companies are increasingly recognizing the value of Chinese innovative drug assets, shifting from high-risk acquisitions to strategic partnerships [3]. - Innovent's growth strategy includes reducing reliance on external collaborations while enhancing its own research and development capabilities [13]. - The company is positioned to leverage its partnerships to enhance its competitive edge in the global market, as evidenced by its recent collaborations and product approvals [12][13].